Navigation Links
Delcath Announces First CHEMOSAT Procedures in Germany
Date:2/27/2012

made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: the future use and adoption of the CHEMOSAT system by the J.W. Goethe University Hospital, patient outcome resulting from treatment with the CHEMOSAT system, future initial launch and training agreements with other cancer centers in Europe, CE Marking for the Generation Two system and the timing of our commercial launch in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Simplified Genetics , the only provider ... and safety in the U.S., announced today the launch of ... improved overall health found within specific genes – all with ... The tests include Simply Fit and ... genetic analysis that maps four key genes to provide individuals ...
(Date:9/2/2015)... 2, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... company focused on tissue protection, repair and regeneration, ... and Chief Executive Officer, will present a corporate ... Conference, sponsored by H.C. Wainwright & ... 2015 at the St. Regis Hotel in New ...
(Date:9/2/2015)... SAINT PAUL, Minn. , Sept. 2, 2015 /PRNewswire/ ... company, today scheduled a conference call to discuss its ... ended July 31, 2015. The call will be at ... Company will report financial results for the third quarter ... September 10, 2015. Participants can dial ...
Breaking Medicine Technology:Simplified Genetics Decodes DNA's Blueprint for Individual Health and Safety 2Simplified Genetics Decodes DNA's Blueprint for Individual Health and Safety 3RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3MGC Diagnostics Corporation to Report Third Quarter Fiscal 2015 Financial Results on Thursday, September 10, 2015 2
(Date:9/2/2015)... ... September 02, 2015 , ... A third party administrator (TPA) ... seeing a significant increase in unlawful tactics used by out-of-network (OON) ambulatory surgical ... of OON ASCs encouraging members to have elective procedures done at their facilities ...
(Date:9/2/2015)... ... 2015 , ... Amada Senior Care, premier provider of in-home care and assisted ... County location. Amada franchise partners Mike and Mell Fleming came to the senior ... over 20 years in medical device sales while Mell spent over 30 years as ...
(Date:9/2/2015)... ... September 02, 2015 , ... EDAC Systems, Inc., ... management solutions and services to both government and commercial clients, today announced the ... utility for IBM’s Datacap document capture platform. EDAC PurePAGE processes and enhances ...
(Date:9/2/2015)... ... 2015 , ... “ G-Hold ” was featured on NewsWatch as part of ... consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review ... a tablet while reducing the likelihood of it dropping. , Tablets like the iPad ...
(Date:9/2/2015)... , ... September 02, 2015 , ... Pentec Health, Inc., ... Inc. 5000 List for an impressive sixth consecutive year. Less than 5 % of ... twelve firms in the “health” sector. Pentec’s 3-year revenue growth rate of 65% ...
Breaking Medicine News(10 mins):Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 2Health News:TPA Cracks Down on Forbidden Tactics Used by Out-of-Network Surgical Centers 3Health News:Amada Senior Care Expands to Greater Kansas City 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2
... a Phase 1 clinical trial on a new experimental ... first new class of anti-TB drugs in the past ... and drug-resistant TB. The study is the first ... the National Institutes of Health through the Hinckley-based research ...
... protecting bikers, brains, may also be contributing to hearing ... find out why. The distinctive roar of a ... biggest source of noise for motorcyclists is actually generated ... legal speeds, the sound can exceed safe levels. Now, ...
... have received a major funding boost of 550,000 from ... into the pathological processes underpinning Alzheimer,s disease, the most ... the UK. The funding will be used to ... electrical signalling go wrong in the Alzheimer,s disease brain. ...
... (HealthDay News) -- Low blood pressure while undergoing dialysis ... blood vessels are connected to the dialysis machine, a ... a sudden drop in blood pressure during dialysis can ... and long-term problems such as stroke, seizure, heart damage ...
... research focusing on high-frequency oscillations, termed ripples and ... provide an important marker for the localization of ... to the study now available in Epilepsia ... Epilepsy (ILAE), the resection of brain regions containing ...
... Crawford, PhD, a clinical associate professor of psychiatry and ... at Boston University School of Medicine (BUSM), has been ... Excellence in Diversity Training by the Association of Psychology ... presented to Crawford during the American Psychological Association,s Convention ...
Cached Medicine News:Health News:Scientists receive funding boost to further research into disease mechanisms of Alzheimer’s 2Health News:Blood Pressure Drop During Dialysis May Raise Clot Risk 2Health News:Fast ripples confirmed to be valuable biomarker of area responsible for seizure activity in children 2
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: